# Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

> **NCT05982275** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 25 (estimated)

## Conditions studied

- Multiple Myeloma
- Allogeneic Stem Cell Transplantation

## Interventions

- **GENETIC:** CARTemis-1

## Key facts

- **NCT ID:** NCT05982275
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982275, "Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05982275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*